BioVie, Inc. (BIVI)
| Market Cap | 213.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68.84M |
| Shares Out | 13.92M |
| EPS (ttm) | -9.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $15.35 |
| Previous Close | $13.20 |
| Change ($) | 2.15 |
| Change (%) | 16.29% |
| Day's Open | 13.48 |
| Day's Range | 13.48 - 15.73 |
| Day's Volume | 94,630 |
| 52-Week Range | 7.50 - 46.10 |
News
SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver dise...
About BIVI
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
| Industry Biotechnology | Founded 2013 |
| Stock Exchange NASDAQ | Ticker Symbol BIVI |
Analyst Forecasts
According to one analyst, the rating for BioVie stock is "Strong Buy" and the 12-month stock price forecast is 47.00.